 PALO ALTO, Calif., Nov. 16, 2020 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a poster presentation of two case studies from the... 